debt_leverage_profile
0.35x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; minimal long-term debt, but rising rates increase cost of future equity/debt financing for cash-burning clinical-stage biotech
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) San Diego/US-based lipid nanoparticle raw material suppliers; 2) Asian API manufacturers for mRNA synthesis inputs
Inferred
Agent_Inference
international_expansion_readiness
Primarily USD-denominated partnerships (CSL, Ultragenyx); limited direct international revenue exposure reduces sovereign currency devaluation risk materially
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in San Diego, USA; partnership revenues in USD; minimal direct exposure to JPY, EUR, or AUD devaluation risk
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High; LUNAR lipid nanoparticle delivery technology is proprietary but depends on specialized contract manufacturers; single-source lipid suppliers likely exceed 30% input cost
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption moderate; research data and bioinformatics rely on cloud, but core mRNA/LNP lab work is physical; 30-day termination would disrupt operations 2-4 weeks
Inferred
Agent_Inference
business_model_type_secondary
Biotech drug developer with partnership/licensing revenue model; secondary reliance on cloud for genomics data analysis and collaboration tools
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk; bioinformatics pipelines tied to specific cloud ML tools, but core IP is proprietary lab-based platform, not software-dependent
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue derives from licensing biotech IP and R&D partnerships, not investment contracts; equity is standard registered security
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; handles patient genomic/clinical trial data subject to GDPR (EU trials) and HIPAA; CCPA exposure limited given B2B focus and minimal direct consumer data
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche mRNA therapeutics market, no dominant market position; competitive landscape includes Moderna, BioNTech but no predatory pricing concerns
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~90% recurring via multi-year licensing/collaboration agreements (CSL Behring, Ultragenyx, AstraZeneca); ~10% milestone-triggered transactional payments
Inferred
Agent_Inference
monetization_vector
Licensing fees plus milestone payments from pharma/biotech partners; future royalty streams upon product approval; no direct product revenue yet
Inferred
Agent_Inference
pricing_architecture
Cost-plus/value-based licensing fees; milestone pricing tied to clinical success; stress scenario: partner program cancellations could eliminate 50-70% of revenue
Inferred
Agent_Inference
pricing_power_rating
Moderate; LUNAR LNP platform differentiated but faces competition from Alnylam, Moderna LNP tech; pricing power contingent on clinical success milestones
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 70-85% on licensing/collaboration revenue; currently negative at operating level due to R&D burn exceeding collaboration income
Inferred
Agent_Inference
churn_vulnerability_index
Low free-rider leakage; proprietary LUNAR technology protected by patents; partnership agreements include exclusivity clauses limiting unauthorized use
Inferred
Agent_Inference
headcount_cost_structure
Sublinear at scale; doubling revenue via new partnerships requires modest incremental headcount in business development and research, not proportional scaling
Inferred
Agent_Inference
marginal_cost_of_growth
Low marginal cost for additional licensing deals; incremental R&D scientists needed but platform leverage means each new program costs less than prior ones
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC remains low (BD-driven enterprise deals); LTV/CAC ratio strong if royalty streams materialize; key risk is pipeline attrition reducing partner count
Inferred
Agent_Inference
network_effect_present
Weak network effects; platform value grows with data/IP accumulation but no direct user network effect; competitive moat is IP and scientific expertise
Inferred
Agent_Inference
asset_efficiency_ratio
-24.3% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-low recession resistance; pharma partner R&D budgets can be cut in deep recessions; government/public health vaccine contracts provide partial buffer
Inferred
Agent_Inference
customer_segment_primary
Large pharmaceutical and biotech companies (CSL Behring, Ultragenyx, AstraZeneca) representing >80% of collaboration revenue; high concentration risk
Inferred
Agent_Inference
customer_segment_secondary
Government/public health agencies for mRNA vaccine development; early-stage revenue but strategically important for pipeline diversification
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.3% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001768224
High
SEC-EDGAR
ticker
ARCT
High
SEC-EDGAR